Trial Profile
An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vupanorsen (Primary)
- Indications Hyperlipoproteinaemia type I; Hypertriglyceridaemia; Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors Akcea Therapeutics
- 16 Jun 2020 Results assessing early efficacy and safety of a strategy that targets ANGPTL3 via ISIS-703802 (AKCEA-ANGPTL3-LRx) in patients with FPLD, were presented at the 80th Annual Scientific Sessions of the American Diabetes Association.
- 11 Sep 2019 Status changed from active, no longer recruiting to completed.
- 16 Jan 2019 Planned End Date changed from 30 Apr 2019 to 30 Aug 2019.